mg day are recommended and preferably about 0 1 10 mg day depending on the potency of the agent in the combination of the present invention the bisphosphonic acid and the agent binds to the adrogen receptor may be administered separately or in combination in addition the administration of one element may be prior to concurrently with or subsequent to the administration of the other agent the active ingredients of the combination of the present invention may be administered by oral parenteral e g intramuscular intraperitoneal intravenous or subcutaneous injection or implant nasal vaginal rectal sublingual or topical routes of administration and may be formulated alone or together in suitable dosage unit formulations containing conventional non toxic pharmaceutically acceptable carriers adjuvants and vehicles appropriate for each route of administration the pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients in general the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both and then if necessary shaping the product into the desired formulation in the pharmaceutical composition the active ingredient s is included in an amount sufficient to produce the desired effect upon the process or condition of the disease the pharmaceutical compositions containing the active ingredient s suitable for oral administration may be in the form of discrete units such as hard or soft capsules tablets troches or lozenges each containing a predetermined amount of the active.